Breast cancer therapy has traditionally relied on a combination of surgery, radiation, chemotherapy, and hormonal treatments. However, these modalities frequently suffer from limitations such as non-specific targeting, adverse side effects, and eventual drug resistance. Nanostructure-based strategies have emerged as a promising avenue to circumvent these obstacles by exploiting the unique physicochemical properties of nanomaterials, enabling precise delivery of therapeutic agents directly to malignant cells. This approach offers a paradigm shift from broad-spectrum cytotoxicity to targeted and personalized medicine.

The core advantage of nanostructures lies in their ultrasmall size, typically ranging from 1 to 100 nanometers, and their ability to be engineered with specific surface chemistries. Such modifications permit functionalization with targeting ligands, antibodies, or peptides that recognize and bind to cancer cell biomarkers. This enhanced specificity not only increases drug accumulation within tumor tissues via enhanced permeability and retention (EPR) effects but also reduces off-target damage, preserving healthy tissues. Additionally, nanocarriers can be designed to release payloads in response to stimuli such as pH changes, temperature fluctuations, or enzymatic activity characteristic of the tumor microenvironment.

Among the most explored nanostructures are liposomes, dendrimers, polymeric nanoparticles, metallic nanostructures, and quantum dots. Liposomes, phospholipid-based vesicles capable of encapsulating both hydrophilic and lipophilic drugs, have undergone clinical success due to their biocompatibility and ability to evade immune clearance when appropriately PEGylated. Dendrimers, with their highly branched synthetic architecture, offer unparalleled control over size and surface functionality, facilitating multivalent interactions with cancer cells. Polymeric nanoparticles, often synthesized from biodegradable polymers like PLGA, provide sustained drug release profiles with low toxicity.

Recent advances in metallic nanostructures, including gold and silver nanoparticles, have opened new horizons for breast cancer therapy, particularly in photothermal and photodynamic modalities. These nanoparticles possess unique optical properties enabling them to convert absorbed light into heat, selectively ablating tumor tissues upon irradiation. Such therapies harness minimally invasive techniques, reducing collateral damage and improving patient recovery times. Moreover, when conjugated with chemotherapeutic agents, metallic nanoparticles can serve dual functions—enhancing therapeutic accumulation and enabling external control over drug activity.

The challenges confronted by nanostructure-based breast cancer therapies, however, are multifaceted. A primary concern is the heterogeneity of tumor physiology, which complicates uniform nanoparticle distribution and penetration within the tumor mass. The dense extracellular matrix and abnormal vasculature often restrict nanocarrier accessibility, necessitating the development of strategies to augment tumor penetration. Modulating nanoparticle size, shape, and surface charge plays a crucial role, but biological barriers such as the mononuclear phagocyte system (MPS) often clear nanoparticles before they reach their targets.

Immunogenicity and long-term toxicity remain significant hurdles. Although many nanomaterials exhibit biocompatibility, chronic exposure and accumulation in organs like the liver and spleen pose safety concerns. Detailed pharmacokinetic and pharmacodynamic studies are essential to elucidate biodistribution patterns and potential adverse effects. The inherent complexity and variability across patients call for personalized nanomedicine approaches, leveraging biomarker profiling to tailor nanotherapeutic designs.

Regulatory frameworks for nanomedicines are still evolving. Standardization of characterization methods, manufacturing reproducibility, and quality control are critical to ensure clinical translation and patient safety. Integration with advanced imaging techniques allows real-time monitoring of nanocarrier distribution and therapeutic outcomes, providing invaluable feedback for optimizing treatment regimens. Combining nanostructures with immunotherapy agents represents another frontier, aiming to potentiate the host immune response against breast cancer cells.

The future directions highlighted in this research emphasize a multidisciplinary approach, involving materials science, molecular biology, and clinical oncology. Innovations such as stimuli-responsive “smart” nanomaterials, multi-drug loaded platforms, and combination therapies integrating nanostructures with gene editing tools like CRISPR/Cas9 promise to redefine breast cancer management. Advances in computational modeling and machine learning can accelerate the design and screening of effective nanotherapeutic candidates. Furthermore, the development of universal docking strategies and modular platforms can facilitate rapid adaptation to emerging cancer subtypes.

In parallel, ethical considerations and equitable access to these advanced therapies must not be overlooked. The high costs associated with nanomedicine development may limit availability in low-resource settings, warranting policy initiatives to bridge disparities. Patient education and informed consent remain indispensable components as novel nanotherapies move from bench to bedside.

In conclusion, the dynamic intersection of nanotechnology and breast cancer treatment heralds a transformative era in oncology. By enabling targeted delivery, reducing systemic toxicity, and overcoming drug resistance mechanisms, nanostructure-based strategies hold immense promise to improve survival rates and quality of life for breast cancer patients globally. Continuous collaborative efforts spanning fundamental research, technological innovation, and clinical validation are imperative to translate these breakthroughs into routine clinical practice and ultimately conquer one of the most formidable health challenges of our time.

Subject of Research: Nanostructure-based strategies for breast cancer therapy, including innovations, challenges, and future directions.

Article Title: Correction to: Emerging nanostructure-based strategies for breast cancer therapy: innovations, challenges, and future directions.

Article References:

Hadri, S.H., Riaz, A., Abid, J. et al. Correction to: Emerging nanostructure-based strategies for breast cancer therapy: innovations, challenges, and future directions.
Med Oncol 42, 385 (2025). https://doi.org/10.1007/s12032-025-02876-1

Image Credits: AI Generated

Hormone receptor-positive breast cancers constitute a substantial fraction of breast cancer cases worldwide, often treated initially with endocrine therapies aimed at suppressing estrogen receptor signaling. However, resistance to these therapies frequently arises, leading to disease progression. Fulvestrant, a selective estrogen receptor degrader, has established itself as an essential component in endocrine therapy regimens, particularly in advanced settings. Yet, the development of resistance mechanisms remains a formidable barrier to long-term control. This clinical trial explores the addition of capivasertib—a potent, selective pan-AKT kinase inhibitor—to disrupt intracellular signaling pathways downstream of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR axis, which is often implicated in therapeutic resistance and tumor survival.

The CAPItello-291 trial enrolls a broad patient population characterized by HR-positive and HER2-negative advanced breast cancer, focusing on those with disease progression following prior endocrine therapy. By combining capivasertib with fulvestrant, the study hypothesizes a synergistic effect whereby the blockade of estrogen receptor signaling is reinforced by concurrent inhibition of the AKT-mediated proliferation pathways—a multifaceted assault designed to circumvent the adaptive resistance that typically undermines monotherapy efficacy. This combined regimen represents a targeted therapeutic strategy, harnessing molecular insights into tumor biology to optimize clinical response.

In the context of pharmacodynamics, capivasertib functions by selectively inhibiting AKT, a serine/threonine kinase that acts as a central node transducing survival and growth signals from receptor tyrosine kinases. Dysregulation of the PI3K/AKT/mTOR pathway is frequently observed in breast cancer, and aberrant activation contributes to oncogenesis, cell proliferation, and survival, especially in the context of endocrine resistance. By interfering with AKT activity, capivasertib impairs downstream signaling cascades, potentially sensitizing cancer cells to endocrine agents like fulvestrant.

The Chinese cohort within CAPItello-291 presents an essential opportunity to investigate population-specific pharmacogenomics and drug response profiles. Differences in genetic polymorphisms, tumor mutational landscapes, and pharmacokinetics can influence therapeutic efficacy and safety. Validating the combination therapy’s effectiveness and tolerability in this demographic broadens the universal applicability of treatment recommendations and addresses disparities in clinical outcomes.

Efficacy endpoints in the trial include progression-free survival (PFS), overall response rate (ORR), and clinical benefit rate (CBR), with safety profiles meticulously documented. Preliminary analysis reveals that capivasertib plus fulvestrant significantly extends PFS compared to fulvestrant alone, indicating improved disease control. Encouragingly, the combination exhibits a manageable safety profile, with adverse events consistent with known effects of AKT inhibition and endocrine therapy, such as hyperglycemia, rash, and gastrointestinal symptoms.

From a mechanistic viewpoint, the rationale for targeting the PI3K/AKT/mTOR pathway lies in its critical role in mediating resistance to hormone therapies. Tumor cells frequently activate compensatory survival pathways upon estrogen receptor blockade, with AKT emerging as a central player facilitating cellular adaptation. The dual blockade strategy effectively disrupts the resilience of cancer cells, preventing them from circumventing therapy-induced stress. These molecular insights pave the way for combination regimens becoming standard care in managing resistant breast cancer phenotypes.

Moreover, the integration of biomarker analyses within the trial enhances understanding of patient subgroups most likely to benefit from this therapeutic approach. Genomic alterations such as PIK3CA mutations, PTEN loss, or AKT amplification may serve as predictive markers, allowing for patient stratification and personalized treatment planning. The study’s findings encourage further development of companion diagnostics to optimize patient selection and improve clinical outcomes.

Importantly, the CAPItello-291 findings scoop into an evolving narrative where combination therapies are tailored based on tumor biology rather than histology alone. This paradigm advances precision oncology, shifting away from the one-size-fits-all approach to a more individualized strategy that exploits vulnerabilities within cancer’s molecular circuitry. As a result, patients gain access to more effective treatments with the potential for longer-term remission and improved quality of life.

The trial also underscores the challenges and complexities in translating promising preclinical results into clinical practice. Managing adverse effects requires careful dose optimization and patient monitoring, emphasizing the need for multidisciplinary care involving oncologists, nurses, and supportive care teams. Education on potential side effects and proactive management strategies are critical to maximizing adherence and therapeutic success.

In parallel, the study highlights the critical role of international collaboration in cancer research. By extending trials into diverse populations, researchers can capture variations in disease biology and treatment response, which ultimately refine global treatment guidelines. This inclusive approach ensures that advances in medicine benefit broad patient populations, avoiding regional inequities in outcomes.

The publication of CAPItello-291’s extended data in Nature Communications marks a pivotal contribution to breast cancer literature. It fuels optimism for new therapeutic combinations that may delay or prevent resistance, extending survival in a disease that remains a leading cause of cancer morbidity and mortality among women globally. The knowledge generated propels ongoing drug development pipelines that aim to exploit the vulnerabilities of HR-positive/HER2-negative breast cancer cells.

Furthermore, integrating molecularly targeted agents like capivasertib aligns with the broader oncology movement toward combination regimens that address complex resistance mechanisms. This multifactorial assault strategy differs fundamentally from traditional chemotherapies by sparing normal tissues and focusing therapies precisely on tumor-driven pathways. As such, the therapeutic index improves, offering enhanced efficacy with reduced toxicity.

The extended Chinese cohort findings also provide actionable insights for regulatory bodies considering approval of new drug combinations. They demonstrate robust evidence of clinical benefit within a previously underrepresented population, bolstering confidence in treatment scalability. Regulatory endorsement may facilitate access to these novel therapies, ensuring that patients in various geographic regions can benefit from advances emanating from international research consortia.

Looking ahead, future studies may explore combining capivasertib and fulvestrant with other targeted agents such as CDK4/6 inhibitors or emerging immunotherapies. The evolving understanding of tumor microenvironment and immune modulation opens avenues for integrated treatment approaches that further potentiate anti-tumor responses. The ongoing evolution of therapeutic strategies exemplifies the dynamic nature of breast cancer research.

In conclusion, the CAPItello-291 phase 3 study’s extension to the Chinese cohort affirms the promise of capivasertib combined with fulvestrant as a potent therapeutic duo in HR-positive/HER2-negative advanced breast cancer. By merging molecular targeting with endocrine therapy, this approach addresses the critical clinical challenge of treatment resistance, heralding a new era of precision medicine. These findings set a new benchmark for combination regimens and reinforce the imperative for continued investment in personalized cancer therapies, ultimately improving outcomes for millions of patients worldwide.

Subject of Research: Capivasertib plus fulvestrant treatment efficacy in HR-positive/HER2-negative advanced breast cancer

Article Title: Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

Article References:
Hu, X., Zhang, Q., Sun, T. et al. Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort. Nat Commun 16, 4324 (2025). https://doi.org/10.1038/s41467-025-59210-6

Image Credits: AI Generated

Breast cancer remains one of the most pervasive malignancies worldwide, characterized by its heterogeneous nature and the frequent emergence of drug resistance mechanisms that severely limit treatment efficacy. Current therapeutic strategies often falter when confronted with aggressive breast cancer subtypes, especially triple-negative breast cancer (TNBC), which lacks hormone receptors typically targeted by standard therapies. This grim reality has galvanized research into alternative agents capable of circumventing such resistance, where CBD has emerged as a compelling candidate.

The review conducted by Esmaeli, Dehabadi, and Khaleghi undertakes a rigorous systematic analysis following PRISMA guidelines, encompassing a broad literature search in major databases such as PubMed, Google Scholar, Web of Science, and Scopus. From an initial pool of 1,191 articles, 34 studies spanning nearly three decades were distilled for their methodological rigor and relevance to the antitumor effects of CBD. The selected research integrates in vitro cellular assays, in vivo animal models, and early-phase clinical trials, creating a multidimensional perspective on CBD’s actions.

At the cellular level, CBD has demonstrated profound influences on breast cancer pathophysiology. It induces apoptosis—the programmed cell death critical to removing malignant cells—while simultaneously inhibiting key processes like cell proliferation. This dual action disrupts tumor growth dynamics, halting progression effectively in laboratory and animal studies. Notably, CBD also suppresses metastatic spread, which is the principal cause of mortality in breast cancer patients, by modulating tumor microenvironment factors that promote invasion and migration.

Digging deeper into the molecular mechanisms, the review highlights CBD’s capacity to interact with multiple signaling pathways integral to cancer cell survival and metabolism. It modulates the PI3K/Akt and mTOR pathways, both of which are hyperactivated in many cancers and associated with aggressive phenotypes and treatment resistance. Furthermore, CBD engages nuclear receptors such as PPARγ, influencing gene expression patterns that regulate cellular differentiation, apoptosis, and inflammation.

An intriguing aspect of CBD’s mechanism involves its interaction with cannabinoid receptors CB1 and CB2, as well as non-cannabinoid receptors. These interactions form a complex network through which CBD exerts immunomodulatory and anti-inflammatory effects, thereby influencing tumor immune surveillance and stromal support. The review underscores that CBD’s multi-targeted approach may be particularly advantageous in treating TNBC, where receptor-targeted therapies are ineffective, and conventional chemotherapy often leads to adverse side effects.

Preclinical studies overwhelmingly support CBD’s anticancer efficacy, yet the clinical landscape remains nascent, marked by a handful of exploratory trials. These early human studies suggest that CBD can function as a valuable adjunct to existing chemotherapeutic regimens, potentially enhancing therapeutic outcomes and mitigating toxicity. However, the review points out that heterogeneity in study design, varying CBD preparations and dosages, and the lack of standardized protocols constitute significant barriers to definitive clinical adoption.

Despite these challenges, the prospect of incorporating CBD into breast cancer therapy is tantalizing. Its relatively favorable safety profile, coupled with its ability to modulate critical oncogenic pathways, positions it as a unique agent in the armamentarium against resistant breast cancer subtypes. The review advocates for meticulously designed clinical trials to validate CBD’s efficacy and safety profiles while also identifying predictive biomarkers that could guide patient selection for personalized treatment strategies.

The translational potential of CBD extends beyond direct tumoricidal effects. By modulating the tumor microenvironment—including immune cell infiltration, angiogenesis, and stromal support—CBD could reshape the local niche to inhibit tumor progression and enhance the efficacy of immunotherapies. This expanded scope of activity adds a versatile dimension to CBD’s therapeutic promise, positioning it at the frontier of novel breast cancer treatment paradigms.

Moreover, the review addresses the urgent need for combinatorial therapeutic approaches, wherein CBD could be integrated synergistically with conventional chemotherapies, targeted agents, or emerging immunomodulators. Such strategies could exploit complementary mechanisms of action, potentially overcoming resistance pathways that limit single-agent effectiveness. This concept of combinatorial modulation epitomizes the shift towards precision oncology, aiming to tailor therapies to tumor-specific molecular landscapes.

As research progresses, standardization in CBD formulation and administration becomes paramount. Variability in extraction processes, purity, dosing, and delivery methods currently obfuscates comparative analyses and clinical reproducibility. The review underscores initiatives to establish rigorous quality control and pharmacokinetic profiling, which will be crucial for translating promising preclinical findings into clinically viable treatment options.

In tandem with experimental endeavors, elucidating CBD’s pharmacodynamics and potential off-target effects is critical. While its non-psychoactive nature distinguishes it from other cannabinoids, subtle interactions within the endocannabinoid system and other receptor networks necessitate comprehensive safety assessments. Long-term studies will be indispensable to ascertain tolerability and to preempt any unforeseen adverse reactions in vulnerable patient populations.

The intersection of cancer biology and cannabinoid pharmacology, as exemplified by this extensive review, marks an exciting frontier with transformative potential. The synthesis presented in BMC Cancer provides a compelling scientific rationale for continued exploration of CBD, laying the groundwork for future clinical innovations that may redefine breast cancer management.

In conclusion, cannabidiol emerges as a promising and multifaceted therapeutic agent against breast cancer, with particular efficacy noted in aggressive subtypes like TNBC. Although numerous obstacles remain—including standardization of clinical protocols and validation through robust trials—the groundwork is set for CBD to become an integral part of conventional and personalized oncology regimens. Continued interdisciplinary research will be vital to unlock the full therapeutic potential of this intriguing compound and to bring new hope to patients battling breast cancer worldwide.

Subject of Research: Cannabidiol (CBD) as an antitumor therapeutic agent in breast cancer

Article Title: Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature

Article References:
Esmaeli, M., Dehabadi, M.D. & Khaleghi, A.A. Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature. BMC Cancer 25, 772 (2025). https://doi.org/10.1186/s12885-025-14175-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14175-z